Marketed By
astellas
Pack of
10 Capsules in Strip
Salt Composition
Tacrolimus
Storage
Keep in cold Place
₹400₹656.25
39.05% Off
Tax: ₹48
1
Advagraf 0.5mg Capsule
Delivering To: —
All Substitutes
Overview
Advagraf 0.5mg Capsule is medicine that is given after transplant, to safe the body from rejecting a new organ (heart, liver or kidney). This class of medicine belongs to immunosuppressants, it functions by weakening the immune system, so that it does not attack the new organs of the body.
Indication
Organ Transplant
Uses
Prevention of organ rejection in transplant patients
Benefits
Side Effects
Undesired symptoms or responses vary from person to person as the human body reacts differently to the Advagraf 0.5mg Capsule, but they typically resolve naturally within a few days as the body adjusts to the medicine, requiring no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team. Some of the common side effects of the Advagraf 0.5mg Capsule are:
Fatigue Headache, infection Fever
Loss of appetite
High blood pressure
lack of sleep
Indigestion
Nausea
diarrhea, or constipation, kidney damage
How To Use
Advagraf 0.5mg Capsule should not be taken by anybody with a history of renal, hepatic, cardiovascular, hypoglycemia, or fluid retention. It can be taken on an empty or full stomach as prescribed by your doctor. It's recommended to inform your doctor before taking any other drugs because Advagraf 0.5mg Capsule can interact with them. It is not recommended to break, crush, or chew the drug.
How It Works
Advagraf 0.5mg Capsule is used to suppress the body's immune system. It is an immunosuppressant that helps the body accept the new organ after transplant (heart, liver, and kidney). Advagraf 0.5mg Capsule consists of tacrolimus that binds to FKBP-12, and it inhibits calcineurin and IL-2 production, and as a result immune response is suppressed.
Safety Advice
Alcohol
consult your doctor
Excessive alcohol consumption can decrease the immunity of the individual and weaken the liver function. However, moderate levels of alcohol do not interfere with the working of the Advagraf 0.5mg Capsule, as per the research.
Pregnancy
consult your doctor
The Advagraf 0.5 mg Capsule should be injected after consulting the doctor; during pregnancy, it is not suggested to take it routinely. Advagraf 0.5mg Capsule can be injected in case of severe, life-threatening conditions. However, it may harm the unborn.
Breast Feeding
consult your doctor
The Advagraf 0.5mg Capsule is considered unsafe to be taken while breastfeeding, as there is a chance that it may pass to the developing baby through the breast milk of the mother. It is generally considered unsafe, and there is no clear evidence found in the clinical data of how it harms the baby.
Driving
unsafe
Driving after taking the Advagraf 0.5mg Capsule affect or interfere with driving ability or disturb while operating machinery. Fever or dizziness, neurological effects can be seen after taking the capsule, avoid driving until you feel better.
Kidney
safe if prescribed
The Advagraf 0.5mg Capsule is considered unsafe for people with kidney problems. It can damage the kidneys. Tacrolimus, present in the capsule, is nephrotoxic.
Liver
safe if prescribed
The Advagraf 0.5mg Capsule is generally considered unsafe for people with mild to moderate liver disease. Although regular monitoring of the enzyme is required. The dose should be adjusted; take it with caution.
Missed Doses
Quick Tips
FAQs
Advagraf 0.5mg Capsule is used to suppress the body's immune system. It is an immunosuppressant that helps the body to accept the new organ after transplant (heart, liver, and kidney). Advagraf 0.5mg Capsule consists of tacrolimus that binds to FKBP-12, and it inhibits calcineurin and IL-2 production, and as a result immune response is suppressed.
Inform the doctor if you are allergic to the ingredient present in the Advagraf 0.5mg capsule, in case of high sugar level, pregnant or breastfeeding, or weakened immune system. Patient with medical history or medication.
As the capsule suppresses the immune system so the risk of infection increases. Advagraf 0.5mg Capsule can increase the risk of getting cancer, such as lymph gland cancer (lymphoma) and skin cancer. It can lower the body's ability to fight infections.
Yes, Advagraf 0.5mg Capsule comes under the class macrolides, which is an antibiotic group of medicines. It is used after organ transplantation and helps prevent organ rejection after a heart, kidney, or liver transplant.
It is advised not to take alcohol while taking the Advagraf 0.5mg Capsule, because consuming alcohol can cause serious side effects and can damage your liver badly. Consult your doctor if you have concerns or queries.
As soon as you remember, take the missed dose unless it's time for your next dose. You should never take a double dose to make up for a missed one
Common side effects of the Advagraf 0.5mg Capsule are constipation, muscle pain, swelling, nausea, diarrhea, infection, loss of appetite, hair loss, vomiting, and weakness.
The doctor decides how long the treatment with the Advagraf 0.5mg Capsule will continue, depending on the stage and health of the patient.
During pregnancy, it is not safe to take the Advagraf 0.5mg Capsule, as it can cause harm to the unborn baby. Also, during breastfeeding, this medicine must not be used. Please make sure to consult your healthcare provider regarding the same.
Reference
Hougardy, J. M., Broeders, N., Kianda, M., Massart, A., Madhoun, P., Le Moine, A., ... & Abramowicz, D. (2011). Conversion from Prograf to Advagraf among kidney transplant recipients results in a sustained decrease in tacrolimus exposure. Transplantation, 91(5), 566-569.
Inker, L. A., Astor, B. C., Fox, C. H., Isakova, T., Lash, J. P., Peralta, C. A., ... & Feldman, H. I. (2014). KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. American Journal of Kidney Diseases, 63(5), 713-735.
Manjunatha, T. A., Chng, R., & Yau, W. P. (2021). Efficacy and safety of tacrolimus-based maintenance regimens in de novo kidney transplant recipients: a systematic review and network meta-analysis of randomized controlled trials. Annals of Transplantation, 26, e933588-1.
Staatz, C. E., & Tett, S. E. (2015). Clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients. Clinical pharmacokinetics, 54(10), 993-1025.
Yang, S. S., Choi, J. Y., Cho, W. T., Park, J. B., & Kim, S. J. (2015, April). A single-center, open-label, randomized pilot study to evaluate the safety and efficacy of tacrolimus modified release, Advagraf, versus tacrolimus twice daily, Prograf, in stable renal recipients (single). In Transplantation Proceedings (Vol. 47, No. 3, pp. 617-621). Elsevier.
Ratings And Reviews
4.75/5
4 Ratings
5 Star
75.00%
4 Star
25.00%
3 Star
0.00%
2 Star
0.00%
1 Star
0.00%
a year ago
a year ago
View All Reviews
Related Products
MARKETER DETAILS
astellas
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.